Dermapharm Holding SE has the Profitability Rank of 9. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Dermapharm Holding SE Profitability Rank Related Terms
CHIX:DMPD vs ZTS, UTHR, VTRS: Profitability Rank Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Profitability Rank vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Profitability Rank falls into.
Dermapharm Holding SE Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Dermapharm Holding SE has the Profitability Rank of 9. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a Profitability Rank of 9 as of Mar. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Dermapharm Holding SE and its competitors. This is 13% above median its historical median of 8.00. Over the past decade, Dermapharm Holding SE's Profitability Rank has ranged from 5.00 to 10.00.
Is Dermapharm Holding SE's Profitability Rank too high?
Dermapharm Holding SE's current Profitability Rank of 9 is 13% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Profitability Rank compare to ZTS and UTHR?
Dermapharm Holding SE's Profitability Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, Dermapharm Holding SE's own Profitability Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Drug Manufacturers company?
A good Profitability Rank depends on the Drug Manufacturers industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Profitability Rank is 9, which is 13% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Profitability Rank of 9. The stock's GF Value™ is €39.87, compared to a current price of €46.18 — trading 15.8% above its estimated fair value. The current Profitability Rank is 9, which is 13% above median its 10-year median of 8.00. Dermapharm Holding SE's overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Profitability Rank is 9 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 15.8% above its estimated GF Value™ of €39.87.
Key valuation signals for CHIX:DMPD:
Profitability Rank: 9 (13% above median its 10-year median of 8.00)
GF Value™: €39.87 vs. price of €46.18 (15.8% above fair value)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 